GS621763 is an oral nucleoside analog of Remdesivir against SARS-CoV-2 pathogenesis in mice. GS-621763, an orally bioavailable prodrug of GS-441524, the parental nucleoside of Remdesivir, which targets the highly conserved RNA-dependent RNA polymerase. GS-621763 exhibited significant antiviral activity in lung cell lines and two different human primary lung cell culture systems. The dose-proportional pharmacokinetic profile observed after oral administration of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2. Therapeutic GS-621763 significantly reduced viral load, lung pathology, and improved pulmonary function in COVID-19 mouse model. The deuterated derivative is called VV116 or Deuremidevir (Cat# 556084 and Cat#333114)
MedKoo Cat#: 465727
Name: GS621763
CAS#: 2647442-13-3 (non-label)
Chemical Formula: C24H31N5O7
Exact Mass: 501.2223
Molecular Weight: 501.54
Elemental Analysis: C, 57.48; H, 6.23; N, 13.96; O, 22.33
The following data is based on the product molecular weight 501.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
